Skip to content
The Cancer History Project
HOME
ABOUT
THE CANCER HISTORY PROJECT
THE CANCER LETTER
EDITORIAL BOARD
SPONSORS
CONTRIBUTORS
TCL ARCHIVES
LATEST ARTICLES
Search for:
Search
ARCHIVES
Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer
This article is from
The Cancer Letter
archive.
Vol. 25 No. 7 | July 26, 2002
Download PDF
Visit The Full Archive
Related Articles
TCL Archive
Crout Resigns As Director Of FDA Drugs Bureau
July 11, 1980
TCL Archive
NCI Plans Phase-Out Of K04 Career Awards
March 3, 1995
TCL Archive
NCI Advisory Group, Other Cancer Meetings
June 2, 1989
TCL Archive
Old MSK Grant Reprogrammed, NIC Makes Final 1985 Construction Awards
July 5, 1985
TCL Archive
Longer List of DCPC Spending Plans $40 Mll Increase
December 10, 1993
TCL Archive
Family History of BRCA Mutation Does Not Equal Increased Risk
October 28, 2011